Clinical trial · Observational
Oxford Ovarian Cancer Predict Chemotherapy Response 01
A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
NCT01770535CI-TRIAL-00008971OXO-PCR-01unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between βIII tubulin expression and Mitotic Index (MI) following single agent paclitaxel treatment
- timeFrame
- Before and 24-hours after paclitaxel treatment
- description
- Correlation between βIII tubulin expression and Mitotic Index (MI) before and after single agent paclitaxel treatment to determine whether overexpression of βIII tubulin is associated with Paclitaxel resistance
Secondary outcomes (1)
- measure
- Correlation between mitotic index and the magnitude of CA125 response
- timeFrame
- three weeks after paclitaxel treatment
- description
- Correlation between mitotic index and the magnitude of CA125 response will be analysed to investigate whether post-paclitaxel mitotic index is a determinant of clinical response in ovarian cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female ≥ 18 years of age * Newly diagnosed and histology confirmed primary high grade serous ovarian cancer, high grade serous fallopian tube cancer and primary peritoneal carcinoma. * Radiological and laparoscopic confirmation of FIGO stage 3C or 4 ovarian cancer. * Radiological evidence of omental or peritoneal deposits that are accessible for radiology-guided biopsy. * At least one lesion on CT scan measuring at least 2 cm in maximum diameter performed in the past 31 days. Slightly older scans may be accepted at the discretion of the CI providing the results are considered to remain clinically relevant. * Eastern Cooperative Oncology Group (ECOG) performance score of 0-2 * Life expectancy of at least 6 months. * The patient is willing and able to provide written informed consent and comply with the protocol for the duration of the study, and scheduled visits and examinations. * Acceptable haematological and biochemical indices Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.